Pyramid Biosciences Inc. and Genequantum Healthcare (Suzhou) Co. Ltd. have entered into an exclusive license agreement to develop and commercialize GQ-1010, a potential best-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan).